SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-297530
Filing Date
2022-12-02
Accepted
2022-12-02 16:05:56
Documents
13
Period of Report
2022-12-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d423713d8k.htm   iXBRL 8-K 31854
2 EX-3.1 d423713dex31.htm EX-3.1 130950
  Complete submission text file 0001193125-22-297530.txt   314777

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20221202.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20221202_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20221202_pre.xml EX-101.PRE 11705
7 EXTRACTED XBRL INSTANCE DOCUMENT d423713d8k_htm.xml XML 3549
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 221441961
SIC: 2834 Pharmaceutical Preparations